Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Donald Trump’s threat to impose a 50 per cent tariff on all exports from the EU would deliver a hammer blow to key ...

Diabetes is a leading global health and economic challenge, affecting over 800 million people worldwide, with over 80% ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

During the third quarter, the Lazard International Equity Advantage Portfolio underperformed the MSCI EAFE Index (net of fees ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

The global sales of peptide therapeutics is estimated to be worth USD 42.1 billion in 2024 and anticipated to reach a value ...